• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迈向基于脂质制剂的标准化体外测试的建立,第4部分:提出一种新的脂质制剂性能分类系统。

Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.

作者信息

Williams Hywel D, Sassene Philip, Kleberg Karen, Calderone Marilyn, Igonin Annabel, Jule Eduardo, Vertommen Jan, Blundell Ross, Benameur Hassan, Müllertz Anette, Porter Christopher J H, Pouton Colin W

机构信息

Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, 3052, Australia; Capsugel R&D, Strasbourg, France.

出版信息

J Pharm Sci. 2014 Aug;103(8):2441-55. doi: 10.1002/jps.24067. Epub 2014 Jul 1.

DOI:10.1002/jps.24067
PMID:24985238
Abstract

The Lipid Formulation Classification System Consortium looks to develop standardized in vitro tests and to generate much-needed performance criteria for lipid-based formulations (LBFs). This article highlights the value of performing a second, more stressful digestion test to identify LBFs near a performance threshold and to facilitate lead formulation selection in instances where several LBF prototypes perform adequately under standard digestion conditions (but where further discrimination is necessary). Stressed digestion tests can be designed based on an understanding of the factors that affect LBF performance, including the degree of supersaturation generated on dispersion/digestion. Stresses evaluated included decreasing LBF concentration (↓LBF), increasing bile salt, and decreasing pH. Their capacity to stress LBFs was dependent on LBF composition and drug type: ↓LBF was a stressor to medium-chain glyceride-rich LBFs, but not more hydrophilic surfactant-rich LBFs, whereas decreasing pH stressed tolfenamic acid LBFs, but not fenofibrate LBFs. Lastly, a new Performance Classification System, that is, LBF composition independent, is proposed to promote standardized LBF comparisons, encourage robust LBF development, and facilitate dialogue with the regulatory authorities. This classification system is based on the concept that performance evaluations across three in vitro tests, designed to subject a LBF to progressively more challenging conditions, will enable effective LBF discrimination and performance grading.

摘要

脂质制剂分类系统联盟旨在开发标准化的体外测试,并为脂质基制剂(LBF)制定急需的性能标准。本文强调了进行第二次、压力更大的消化测试的价值,以识别接近性能阈值的LBF,并在多个LBF原型在标准消化条件下表现良好(但需要进一步区分)的情况下促进先导制剂的选择。可以基于对影响LBF性能的因素的理解来设计压力消化测试,包括分散/消化时产生的过饱和程度。评估的压力包括降低LBF浓度(↓LBF)、增加胆盐和降低pH值。它们对LBF施加压力的能力取决于LBF的组成和药物类型:↓LBF对富含中链甘油酯的LBF是一种压力源,但对富含亲水性表面活性剂的LBF则不是,而降低pH值会对托芬那酸LBF产生压力,但对非诺贝特LBF则不会。最后,提出了一种新的性能分类系统,即与LBF组成无关,以促进标准化的LBF比较,鼓励强大的LBF开发,并促进与监管机构的对话。该分类系统基于这样一种概念,即通过三项体外测试进行性能评估,旨在使LBF面临逐渐更具挑战性的条件,将能够有效地对LBF进行区分和性能分级。

相似文献

1
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system.迈向基于脂质制剂的标准化体外测试的建立,第4部分:提出一种新的脂质制剂性能分类系统。
J Pharm Sci. 2014 Aug;103(8):2441-55. doi: 10.1002/jps.24067. Epub 2014 Jul 1.
2
In vitro assessment of drug-free and fenofibrate-containing lipid formulations using dispersion and digestion testing gives detailed insights into the likely fate of formulations in the intestine.采用分散和消化试验对无药物和非诺贝特载脂体制剂进行体外评估,可深入了解制剂在肠道中的可能命运。
Eur J Pharm Sci. 2013 Jul 16;49(4):748-60. doi: 10.1016/j.ejps.2013.04.036. Epub 2013 May 16.
3
Toward the establishment of standardized in vitro tests for lipid-based formulations. 2. The effect of bile salt concentration and drug loading on the performance of type I, II, IIIA, IIIB, and IV formulations during in vitro digestion.为了建立标准化的基于脂质的制剂的体外测试方法。2. 胆汁盐浓度和药物载药量对 I 型、II 型、IIIA 型、IIIB 型和 IV 型制剂在体外消化过程中的性能的影响。
Mol Pharm. 2012 Nov 5;9(11):3286-300. doi: 10.1021/mp300331z. Epub 2012 Oct 22.
4
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 3: understanding supersaturation versus precipitation potential during the in vitro digestion of type I, II, IIIA, IIIB and IV lipid-based formulations.为了建立标准化的基于脂质的制剂的体外测试,第 3 部分:了解 I 型、II 型、IIIA 型、IIIB 型和 IV 型基于脂质的制剂在体外消化过程中的过饱和度与沉淀潜力。
Pharm Res. 2013 Dec;30(12):3059-76. doi: 10.1007/s11095-013-1038-z. Epub 2013 May 10.
5
Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.聚合物沉淀抑制剂促进非诺贝特过饱和并增强 IV 型脂肪乳剂配方的药物吸收。
Mol Pharm. 2018 Jun 4;15(6):2355-2371. doi: 10.1021/acs.molpharmaceut.8b00206. Epub 2018 May 4.
6
Correlating in Vitro Solubilization and Supersaturation Profiles with in Vivo Exposure for Lipid Based Formulations of the CETP Inhibitor CP-532,623.将 CETP 抑制剂 CP-532,623 的脂质体制剂的体外溶解和超饱和度曲线与体内暴露相关联。
Mol Pharm. 2017 Dec 4;14(12):4525-4538. doi: 10.1021/acs.molpharmaceut.7b00660. Epub 2017 Nov 9.
7
Effect of lipids on absorption of carvedilol in dogs: Is coadministration of lipids as efficient as a lipid-based formulation?脂肪对犬体内卡维地洛吸收的影响:与脂肪制剂相比,同时给予脂肪是否同样有效?
J Control Release. 2019 Jun 28;304:90-100. doi: 10.1016/j.jconrel.2019.04.038. Epub 2019 Apr 29.
8
Toward the establishment of standardized in vitro tests for lipid-based formulations, part 1: method parameterization and comparison of in vitro digestion profiles across a range of representative formulations.为了建立标准化的基于脂质的制剂的体外测试方法,第 1 部分:方法参数化以及对一系列代表性制剂的体外消化曲线的比较。
J Pharm Sci. 2012 Sep;101(9):3360-80. doi: 10.1002/jps.23205. Epub 2012 May 29.
9
Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.设计用于口服给药的脂基制剂:对消化的影响
AAPS PharmSciTech. 2012 Jun;13(2):637-46. doi: 10.1208/s12249-012-9787-2. Epub 2012 May 1.
10
Transient Supersaturation Supports Drug Absorption from Lipid-Based Formulations for Short Periods of Time, but Ongoing Solubilization Is Required for Longer Absorption Periods.短暂的过饱和在短时间内支持基于脂质制剂的药物吸收,但较长吸收期需要持续增溶。
Mol Pharm. 2017 Feb 6;14(2):394-405. doi: 10.1021/acs.molpharmaceut.6b00792. Epub 2017 Jan 13.

引用本文的文献

1
and correlation for lipid-based formulations: Current status and future perspectives.基于脂质的制剂的相关性:现状与未来展望。
Acta Pharm Sin B. 2021 Aug;11(8):2469-2487. doi: 10.1016/j.apsb.2021.03.025. Epub 2021 Mar 21.
2
Supersaturation and Solubilization upon In Vitro Digestion of Fenofibrate Type I Lipid Formulations: Effect of Droplet Size, Surfactant Concentration and Lipid Type.非诺贝特 I 型脂质制剂体外消化时的过饱和与增溶作用:液滴大小、表面活性剂浓度和脂质类型的影响
Pharmaceutics. 2021 Aug 18;13(8):1287. doi: 10.3390/pharmaceutics13081287.
3
Self-Nanoemulsifying Drug Delivery System of Genkwanin: A Novel Approach for Anti-Colitis-Associated Colorectal Cancer.
金雀异黄素自微乳给药系统:一种治疗结肠炎相关结直肠癌的新方法。
Drug Des Devel Ther. 2021 Feb 12;15:557-576. doi: 10.2147/DDDT.S292417. eCollection 2021.
4
Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems.过饱和自乳化药物递送系统的现状
Pharmaceutics. 2020 Apr 16;12(4):365. doi: 10.3390/pharmaceutics12040365.
5
Ionic Liquid Forms of the Antimalarial Lumefantrine in Combination with LFCS Type IIIB Lipid-Based Formulations Preferentially Increase Lipid Solubility, In Vitro Solubilization Behavior and In Vivo Exposure.抗疟药卤泛群的离子液体形式与LFCS IIIB型脂质制剂联合使用可优先提高脂溶性、体外溶解行为和体内暴露量。
Pharmaceutics. 2019 Dec 22;12(1):17. doi: 10.3390/pharmaceutics12010017.
6
A new in vitro lipid digestion - in vivo absorption model to evaluate the mechanisms of drug absorption from lipid-based formulations.一种用于评估基于脂质的制剂中药物吸收机制的新型体外脂质消化-体内吸收模型。
Pharm Res. 2016 Apr;33(4):970-82. doi: 10.1007/s11095-015-1843-7. Epub 2015 Dec 24.